Kristin Radcliffe
Director, Medical Affairs Operations Lead Beam Therapeutics Inc.
Kristin Radcliffe is Director, Medical Affairs Operations Lead at Beam Therapeutics, where she leads medical affairs program and operational strategy across the company’s rare disease base-editing portfolio. Her career spans medical affairs, program management and clinical operations across rare disease, oncology and cell and gene therapy. Prior to Beam, Kristin held roles at Umoja Biopharma, Alexion Pharmaceuticals and Sanofi Genzyme, where she managed a global managed access program across 20 countries, bringing direct experience in navigating the operational realities of patient access at scale.
Seminars
Tuesday 23rd March 2027
Workshop F – From Access to Exit: Designing Global Program Closure, Patient Transition & Long-Term Access Strategies
1:30 pm
- Navigating country-by-country closure requirements, reimbursement delays and differing patient continuity obligations across global markets.
- Determining how and when programs should close in markets where launch plans, regulatory outcomes or funding assumptions change.
- Learning from successful and unsuccessful program exits, including the operational, regulatory and stakeholder challenges that emerge once an access program reaches the end of its lifecycle.
- Benchmarking how organizations are handling program winddown, patient communications, physician engagement and long-term access commitments globally
